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Abstract: Hyponatremia is the most common electrolyte abnormality in hospitalized patients 
and is associated with increased morbidity and mortality. The recognition of the central role 
that arginin vasopressin plays in the pathogenesis of hyponatremia and the discovery that its 
actions are mediated by stimulation of V1A and V2 receptors have led to the development of a 
new class of drugs, the arginin vasopressin antagonists. Conivaptan is a nonselective V1A and 
V2 receptors antagonist that was the first of this class to be approved by the FDA for the man-
agement of euvolemic and hypervolemic hyponatremia. Its short-term safety and efficacy for 
the correction of hyponatremia have been established by multiple double-blind, randomized, 
controlled studies. Blocking the effects of arginin vasopressin on V2 receptors produces aqua-
resis – the electrolyte-sparing excretion of water – an ideal approach to correct hypervolemic 
hyponatremia. The nonselectivity of conivaptan offers a theoretical advantage for its use in 
heart failure that may merit further exploration.
Keywords: arginine vasopressin antagonist, conivaptan, heart failure, hyponatremia
Introduction
Hyponatremia is the most common electrolyte abnormality seen in hospitalized 
patients. Although recognized for almost a century, our understanding of hyponatremia 
remains incomplete and its management continues to represent a challenge. The 
presence of inappropriately elevated plasma level of arginine vasopressin (AVP) is 
well established in the vast majority of hyponatremic states, and the development of 
arginine vasopressin antagonists signaled the beginning of a new treatment option for 
hyponatremia. Conivaptan was the first such agent to be approved for this indication 
in euvolemic and hypervolemic states.
This article reviews the pathogenesis of hyponatremia and the pathophysiological 
basis for the development of conivaptan, its properties, the experience accumulated 
from clinical trials, and its current use and potential future role.
Prevalence
The prevalence of hyponatremia varies depending on the definition used, patient 
population, and the frequency of testing.1 When defined as 135 milliequivalent per 
liter (mEq/L or mmol/L), the prevalence was reported in 40,000 hospitalized patients 
at 28% on admission, with the development of hyponatremia in another 14% while in 
the hospital.2 However, figures as low as 5.5% have also been reported.3
In patients with heart failure, using this definition, a prevalence of 20% to 45% has 
been reported in several large registries.4–8 The prevalence would be considerably higher, Drug Design, Development and Therapy 2009:3 254
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however, if a cutoff of 138 mEq/L were adopted to define 
hyponatremia,9 a level below which an increased morbidity 
and mortality was noted in this patient population.8
Clinical manifestations
The clinical manifestations of hyponatremia are related to 
osmotic water shift leading to increased intracellular fluid 
volume causing cerebral edema. Because the surrounding 
cranium limits expansion of the brain, intracranial hyper-
tension develops and may cause brain injury.10–13 Therefore, 
symptoms are primarily neurologic and their severity 
depend on the rapidity of development of hyponatremia and 
its magnitude.10–13 Patients may be asymptomatic or they 
may develop symptoms such as malaise, headache, nausea, 
vomiting, lethargy, depressed reflexes and confusion. As the 
plasma [Na+] falls below 120 mEq/L and especially if the 
disorder has developed rapidly, stupor, seizures, brain stem 
herniation and coma may occur.10–13 Solutes leave the brain 
tissue within hours, thereby inducing water loss and reducing 
brain swelling.13 This adaptive mechanism accounts for the 
relatively asymptomatic nature of even severe hyponatremia 
if it develops slowly.10–14
Pathophysiology
Hyponatremia is defined as a decreased serum [Na+] 
concentration (traditionally 135 mEq/L). Accordingly, 
hyponatremia reflects a disturbance in water rather than 
[Na+] balance, although several interactions between the 
two regulatory systems exist. The definition of hyponatremia 
is based on concentration; therefore it does not provide 
information on extracellular fluid volume (ECF) in which 
[Na+] is measured. As a result, hyponatremia can occur in 
the context of contracted ECF (hypovolemia), normal ECF 
(euovolemia) or expanded ECF (hypervolemia).10
Many conditions can lead to hyponatremia, which 
can be associated with low, normal or high osmolality.14 
Hypo-osmolar hyponatremia is by far the most common 
form of this disorder,10 and is caused by multiple medical 
conditions (Table 1). Hyponatremia can be associated with 
normal plasma osmolality in cases of extreme hyperlipidemia 
or hyperproteinemia (pseudohyponatremia) or high osmo-
lality in hyperglycemia and with mannitol use, secondary 
to a shift of water from the cells to the extracellular 
compartment.10,15,16
Arginine vasopressin
Water balance regulation is primarily designed to control 
serum osmolality and to a lesser extent blood volume,17 and the 
central role of AVP in the pathogenesis of hyponatremia was 
recognized more than half a century ago.18,19
AVP is synthesized primarily in the magnocellular 
neurons of the hypothalamic paraventricular nuclei and in 
the supraoptic nuclei that project to the posterior pituitary.20 
In addition, parvocellular neurons of the paraventricular 
nuclei co-expressing AVP and corticotropin-releasing 
hormone (CRH) coordinate hypothalamic–pituitary–adrenal 
(HPA) system activity and project to the external layer of the 
median eminence, where AVP and CRH are released into 
the hypophyseal portal blood.21 The AVP precursor protein 
contains sequences for 3 separate peptides which split during 
transport down the nerve axon to the posterior pituitary into 
AVP, neurophysin and a glycopeptide.
AVP is regulated by 3 mechanisms: osmoreceptors, 
barorecepors and the rennin-angiotensin aldosterone system 
(RAAS).
Under normal conditions, the release of AVP is primarily 
controlled by the osmoreceptors.22 The serum osmolality 
is sensed by osmoreceptors in several parts of the brain, 
including the supraoptic nuclei of the hypothalamus, the 
subfornical organ, and the organum vasculosum of the 
lamina terminalis.22,23 Osmolality is regulated by thirst and 
renal responsiveness to AVP in addition to AVP release.23 
Alterations of the plasma osmolality are detected by 
Table 1 Causes of hyponatremia
i.  Hyponatremia with normal plasma osmolality (pseudohyponatremia)
  1. Hyperlipidemia
  2. Hyperproteinemia
ii.  Hyponatremia with increased plasma osmolality
  1. Hyperglycemia
  2. Mannitol use
  3. radiographic contrast agents
iii.  Hypo-osmolar (hypotonic) hyponatremia
   A. euvolemic
    1. Syndrome of inappropriate antidiuretic hormone secretion
    2. Hypothyroidism
    3. Glucocorticoid deficiency
    4. Strenuous exercise
    5. Primary polydipsia
    6. Decreased solute intake
  B. Hypervolemic
    1. Heart failure
    2. Cirrhosis
    3. Nephrotic syndrome
    4. PregnancyDrug Design, Development and Therapy 2009:3 255
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the osmoreceptors in the vicinity of the supraoptic and 
paraventricular areas of the anterior hypothalamus, which are 
supplied by blood from the internal carotid. A rise in serum 
osmolality causes water to move through the water channels 
of the osmoreceptor cell membranes, which then causes a 
change in cell volume that leads to an increase in the activity 
of stretch-inhibited cation channels.21 The accelerated action 
potential discharge causes an influx of calcium through a 
voltage-gated calcium channel which triggers a cascade of 
molecular events that ultimately leads to the neurosecretion of 
secretory vesicles containing AVP into the bloodstream.21,22
AVP starts to rise after 1% increase in serum osmolality 
or 5% to 10% decrease in blood volume.17 The second 
mechanism regulating AVP release is mediated by baro-
receptors located in the carotid sinus and stretch receptors 
in the walls of the great veins, atria and pulmonary trunk. 
These receptors are sensitive to changes in circulating blood 
volume triggered by hypotension and/or volume depletion. 
In conditions characterized by arterial underfilling such as 
low cardiac output or decreased systemic vascular resistance 
the baroreceptors generate afferent signals to the vasomotor 
center. This results in activation of efferent pathways in the 
sympathetic nervous system (SNS) leading to increase in the 
rate of AVP secretion by the cells in the paraventricular and 
supraoptic nuclei.24
The third mechanism is related to actions of the 
RAAS,25,26 in which angiotensin II directly stimulates the 
secretion of AVP.
In the majority of patients, hyponatremia develops 
because AVP is secreted nonosmotically, resulting in renal 
water reabsorption. The four mechanisms that can cause 
inappropriate AVP effects27 include: (1) nonosmotic AVP 
release by the posterior pituitary induced by specific stimuli 
to the paraventricular or supraoptic nuclei;24 (2) ectopic AVP 
production;28 (3) factors that may enhance the renal effects 
of AVP;29 and (4) an AVP-like effect caused by an activating 
mutation of the vasopressin-2 receptor.27,30
The neurohypophysial antidiuretic hormone AVP regu-
lates free water reabsorption, body fluid osmolality, blood 
volume, blood pressure, cell contraction, cell proliferation 
and adrenocorticotropic hormone (ACTH) secretion via the 
stimulation of specific G-protein-coupled receptors currently 
classified into V1-vascular receptor (V1A), V2-renal receptor 
(V2) and V3-pituitary receptor (V1B) subtypes.31,32
Vasopressin receptors
The VlA receptors are found mainly on vascular smooth muscle 
cells but also in many tissues, including brain, pituitary, 
hepatic, uterus, renal, adrenal, and platelets,31,32 while the 
V1B, distinguished from the VlA subtype by different agonist 
and antagonist affinities, are expressed in cells of the anterior 
pituitary and throughout the brain, especially in the pyramidal 
neurons of the hippocampus and in the pancreas.33,34 The 
renal receptors (V2) are located on the principal cells of 
the collecting ducts of kidney and in vascular smooth muscle 
and endothelial cells.31,32
Stimulation of the V1A receptor results in vasoconstriction, 
glycogenolysis, platelet aggregation, myocyte hypertrophy, 
anxiety and stress.31,32 While stimulation of the V1B receptor 
results in the release of ACTH.35,36
Stimulation of the V2 receptor results in vasodilatation, 
release of von Willebrand factor and factor 8 as well as water 
retention.31,35 The effect of AVP on vascular contractility is dose-
dependent. At low concentrations, it causes vasoconstriction 
and, at higher concentrations, it causes vasodilatation.37
AVP exerts its actions through binding to typical 
heptahelical transmembrane G-protein-coupled receptors with 
distinct second messenger systems; stimulation of the V1A and 
V1B receptors ultimately results in a considerable increase in 
the cytosolic free calcium as a secondary messenger via phos-
phatidylinosilol hydrolysis and 1,2 diacylglycerol signaling 
pathway. The calcium signal may express its activity through 
a number of binding proteins including calmodulin, gelsolin 
or villin, troponin C or protein kinase C.28
Stimulation of the V2 receptor on the other hand leads to 
the activation of adenylyl cyclase, resulting in an increase 
of intracellular c-AMP, and protein kinase A (PKA), 
which triggers phosphorylation of many proteins including 
aquaporin 2 (AQP-2).31 c-AMP then causes fusion of 
AQP-2 containing intracytoplasmic vesicles with the apical 
plasma membrane of the principal cell, leading to increased 
permeability and thus enhanced water reabsorption.28,31,37
The presence of AQPs in combination with an osmotic 
gradient allows water to move through the baso-lateral plasma 
membrane of the principal cell, returning to the bloodstream 
via the constitutively expressed AQP3 and AQP4 water 
channels.29,38 AVP also increases [Na+] and urea permeability 
in the collecting duct (by increasing the number of the 
epithelial [Na+] channel, ENaC, and the urea transporter, 
UT-A1), thereby maintaining the osmotic and medullary 
interstitial gradients and further stimulating antidiuresis.38
Vasopressin receptors  
antagonists (VRAs)
AVP receptors antagonists were first developed as peptide 
antagonists in the 1960s. These compounds had the Drug Design, Development and Therapy 2009:3 256
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disadvantages of having poor oral bioavailability and 
short half-lives.39 The first nonpeptide V2 antagonist was 
characterized in Japan by Yamamura et al in 1991.40 The 
nonpeptide VRAs were more bioavailable, with longer half-
lives, than the earlier peptide formulations.39
Several nonpeptide VRAs have been studied, and were 
developed as oral or intravenous (iv) formulations. They 
differ in their relative selectivity for the various AVP receptor 
subtypes31 and include tolvaptan (oral, selective V2 VRA) that 
was recently approved by the United States Food and Drug 
Administration (FDA) for the treatment of symptomatic or 
severe hyponatremia (serum [Na+]  125 mEq/L); lixivaptan 
(oral, selective V2 VRA) which is currently under intense 
investigation for its potential role in the treatment of hypo-
natremia in heart failure; and conivaptan, the first approved 
nonpeptide V1A/V2 VRA that will be discussed in more 
details.
It would be useful, however, to first briefly review the 
reasons for the search for more effective modality for the 
treatment of hyponatremia.
Limitations of current treatments 
for hyponatremia
There are many limitations to the use of traditional treatment 
of hyoponatremia.41,42 The infusion of hypertonic saline, 
increasing serum [Na+] by 2 to 4 mEq/L within 2 to 4 hours is 
associated with significant fluid overload and many clinicians 
are uncomfortable using it in patients with volume overload. 
Fluid restriction plays a cornerstone role in the treatment of 
hyponatremia but it is fraught with problem of compliance. 
Lithium has also been used to induce nephrogenic diabetes 
insipidus, but it has many side effects including renal impair-
ment, central nervous system effects and thyroid dysfunction. 
The response is erratic and frequent monitoring is needed to 
ensure that blood levels remain within the therapeutic range. 
Demeclocycline is another treatment option, but it has many 
drawbacks including variable response to treatment, poor 
gastrointestinal tolerance, photosensitivity and renal and 
hepatic toxic effects. Urea has been used in patients with 
severe symptoms as it promotes rapid reduction of brain 
edema without the risk of salt overload that accompany 
hypertonic saline, however, it is not well tolerated due to poor 
palatability and the need for concomitant fluid restriction to 
achieve good results. Finally, diuretics often do not correct 
hypotonic hyponatremia, they may actually contribute to 
hyponatremia by promoting excretion of [Na+] and decreasing 
the excretion of electrolyte-free water. In addition, the 
effectiveness of diuretics is related to the amount of [Na+] 
reaching the loop of Henle and diminished [Na+] delivery 
in advanced heart failure results in diminished diuresis.
Conivaptan (YM087)
Conivaptan hydrochloride is a nonpeptide, benzazepine 
derivative and the only dual V1A and V2 AVP receptor 
antagonist. It has almost no effect on V1B receptors. In vitro 
animal studies have shown that the drug has high affinity 
for both V1A and V2.44 The antagonistic effect of conivaptan 
is concentration dependent and it binds competitively with 
an affinity 10-fold higher for V2 than for V1A recptors45 and 
binds reversibly to both receptors.
Conivaptan was discovered first in Japan by Yamanouchi 
Pharmaceutical Co. Ltd., and further developed in the United 
States, by Astellas Pharma US Inc.43
It is the first AVP receptors antagonist to be approved by 
FDA for the use in the management of refractory euvolemic 
and hypervolemic hyponatremia, as intravenous infusion in 
the inpatient setting.
Pharmacokinetics
The pharmacokinetics of conivaptan has been studied 
using both oral and iv formulations in animals and humans 
(Table 2). In a study in the rat, oral formulation effect was dose 
dependant and persisted for more than 24 hours showing 
possibilities of long duration of action.44,45 In humans, oral 
conivaptan, at a dose of 60 mg, showed 44% bioavailability 
and short half-life in 6 healthy individuals, and its pharma-
codynamic effects persisted for at least 6 hours.46
In a study among healthy male subjects, conivaptan was 
administered as 20 mg loading dose (infused over 30 minutes) 
followed by continuous infusion of 40 mg/day for 3 days. 
Mean Cmax for conivaptan was 619 ng/mL and occurred at 
the end of the loading dose, plasma concentration reached 
a minimum at approximately 12 hours after the start of the 
loading dose, and then gradually increased over the duration 
of the infusion to a mean concentration of 188 ng/mL at the 
end of the infusion. The mean terminal elimination half-
life after conivaptan infusion was 5.0 hours, and the mean 
clearance was 15.2 L/hour.47
Drug formulation and dosing
Conivaptan hydrochloride is a white to off-white or pale 
orange-white powder that is very slightly soluble in water 
(0.15 mg/mL at 23 °C). Conivaptan injection is supplied 
as a sterile liquid in an ampule. Each ampule delivers 
20 mg conivaptan hydrochloride, 1.2 g propylene glycol, 
0.4 g ethanol, and water for injection. Lactic acid is added Drug Design, Development and Therapy 2009:3 257
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for pH adjustment to 3.0.47 A loading dose of 20 mg is 
administered through a large vein given over 30 min followed 
by a maintenance dose of 20 to 40 mg/day for up to 4 days by 
continuous infusion. It is recommended to change the infu-
sion site every 24 hours to avoid infusion site complications. 
Close monitoring of serum [Na+] and volume status is 
recommended so the dose can be adjusted accordingly.
Metabolism
Conivaptan is 99% bound to human plasma protein at 
concentration range of 10 to 1000 ng/mL. It is metabolized 
only by the liver cytochrome P450 isozyme (CYP3A4). The 
pharmacokinetics of oral and iv conivaptan are nonlinear. Four 
metabolites have been identified, and inhibition by conivaptan 
of its own metabolism seems to be the major factor for the 
nonlinearity.47 The pharmacological activity of the metabo-
lites at V1A and V2 receptors ranged from approximately 3% 
to 50% and 50% to 100% that of conivaptan, respectively. 
After 10 mg iv or 20 mg oral dose, approximately 83% is 
excreted in feces, and 12% in urine. Approximately 1% of 
the iv dose is excreted as intact conivaptan in urine within 
24 hours.47 Studies in special populations, including patients 
with renal and hepatic insufficiency, demonstrated higher 
levels of conivaptan after oral intake. Since iv conivaptan 
results in higher exposure to the drug, caution should be used 
in patients with hepatic or renal impairment.47
Drug interaction
Conivaptan is a sensitive substrate as well as a potent 
inhibitor of CYP3A4.43 Concomitant use of conivaptan 
with other drugs metabolized by CYP3A4 could result 
in a significant drug interaction, either by an increase in 
conivaptan levels, or an increase other drug levels and 
potentially their side effects.43 By decreasing clearance 
via CYP3A4, conivaptan can increase the risk of toxicity 
of certain drugs such as midazolam, simvastatin and 
amlodipine. For example, 30 mg/day of iv conivaptan 
resulted in a 3-fold increase in the area under the curve 
(AUC) of simvastatin and was associated with an increased 
incidence of rhabdomyolysis.47 It also decreased the 
systemic clearance of digoxin by approximately 30% and 
thus increased its AUC and Cmax values potentiating digoxin 
toxicity. The pharmacokinetics of conivaptan was unchanged 
with co-administration of either captopril or furosemide. 
There was no observed effect of oral conivaptan on the 
pharmacokinetics or pharmacodynamics of warfarin.47 
The effect of ketoconazole, a potent CYP3A4 inhibitor, on 
the serum levels of iv conivaptan has not been evaluated; 
however, co-administration of 10 mg oral conivaptan 
with 200 mg of ketoconazole resulted in a 4- and 11-fold 
increase in Cmax and AUC of conivaptan, respectively. 
Co-administration of clarithromycin (a strong CYP3A4 
inhibitor) and conivaptan can increase the exposure 
to conivaptan and potentiate its toxicity47 (Table 3).
Precautions, contraindications, side effects
Serum [Na+] level should be strictly monitored during 
treatment to avoid overly rapid increase of serum [Na+] and 
the possible serious permanent neurological complications. 
Conivaptan should be used with caution in patients with renal 
or liver impairment since it can be associated with increased 
systemic exposure and potential side effects.
In pregnant rats and rabbits, conivaptan administration 
has shown a delay in fetal growth, physical development and 
sexual maturation.43,47 Therefore its use in pregnancy is clas-
sified as category C and should be used only if the potential 
Table 2 Pharmacokinetics of conivaptan
Parameter Drug
Cmax (at 0.5 h) 619 ng/mL – median, healthy males (20 mg loading dose/20 mg/day)  
575.8 (144.5 to 764.3) ng/mL – median, hyponatremic patients (20 mg loading dose/20 mg/day) 
781.1 (194.5 to 1373.5) ng/mL – median, hyponatremic patients (20 mg loading dose/40 mg/day)
Tmax 30 min (end of iv loading dose)
vd 32L
t½ variable (secondary to nonlinear kinetics)
Protein binding 99%
Metabolism CYP3A4 (substrate and potent inhibitor); 4 active metabolites identified with minimal clinical effect
elimination eliminated primarily as metabolites (1% recovered intact drug in urine)  
83% feces  
12% urine
Mean clearance 15.2 L/h
Bioavailability 44% absorption with oral conivaptan formulationDrug Design, Development and Therapy 2009:3 258
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benefit justifies the potential risk to the fetus. Conivaptan is 
also contraindicated in lactation as it has been found in the 
milk of lactating animals.47
Conivaptan is contraindicated in hypernatremia, 
hypovolemic hyponatremia, and in those who have hyper-
sensitivity to any of its components. Co-administration 
of conivaptan with potent CYP3A4 inhibitors such as 
ketoconazole, itraconazole, clarithromycin, ritonavir 
and indinavir is also contraindicated.47 In patients with 
hypovolemia or total body fluid depletion, conivaptan can 
potentially precipitate renal failure, ischemic organ damage, 
and shock and thus it is contraindicated.47
Conivaptan administration is usually well tolerated. The 
most common adverse reaction reported with conivaptan 
administration was infusion site reaction (including pain, 
erythema, phlebitis and swelling). This occurred in 52.5% 
of subjects treated with conivaptan 40 mg/day compared 
to 3.3% in the placebo group, in studies involving patients 
and healthy volunteers, and it was the most common reason 
for discontinuation of treatment. A pilot study done among 
patients hospitalized with acute decompenstated heart 
failure showed that infusion site reaction was the most 
reported side effect, and conivipatan was well tolerable 
among this patient population.48 Other reported side effects 
in decreasing order included orthostatic hypotension, fever, 
hypokalemia, hypertension, hypotension, peripheral edema, 
headache, hypomagnesaemia, constipation, diarrhea, 
nausea, vomiting, dry mouth, thirst, polyuria, oral candi-
diasis, pneumonia, urinary tract infection, insomnia and 
confusion. Conivaptan can also potentially precipitate 
renal failure, ischemic organ damage and shock. Common 
adverse reactions in 72 healthy volunteers and 243 patients 
with euvolemic and hypervolemic hyponatremia who 
received 20 mg iv conivaptan loading dose followed by 
40 mg/day iv for 2 to 4 days were reported as follows: 
infusion site phlebitis (32%), infusion site reaction (19%), 
hypokalemia and headache (10%), peripheral edema (8%), 
vomiting and diarrhea (7%), anemia, constipation, infusion 
site erythema, thirst, hyponatremia, hypertension, and 
orthostatic hypotension (6%).49 
The risk of rapid correction 
of hyponatremia
Prompt and adequate treatment of hyponatremia is necessary 
to relieve early symptoms and prevent progression to 
seizures and irreversible brain damage. However rapid 
correction of hyponatremia may cause osmotic demyelin-
ating syndrome (ODS), leading to permanent disability 
or death. In chronic hyponatremia, brain cells lose osmo-
lytes, leading to movement of water out of the cells, 
a mechanism that offers protection from developing cerebral 
edema.50,51 These osmolytes include [Na+], potassium and 
Table 3 Medications with potential for significant drug interactions
Chemotherapeutic agents Calcium channel blockers Others 
Doxorubicin Amlodipine Quinidine
etoposide (BP-16) Diltiazem Buspirone
Tamoxifen Felodipine Zolpidem
vinblastine isradipine Nefazodone
vincristine Lercanidipine Trazodone
Nicardipine Carbamazepine
Nifedipine Glucocorticoids
Nimodipine rifabutin
Nisoldipine
Nitrendipine
verapamil
HMG CoA reductase inhibitors Benzodiazipines Macrolide antibiotics  
(except azithromycin,  
dirithromycin and roxithromycin)
Atorvastatin 60 mg/day Alprazolam
Lovastatin Diazepam
Simvastatin Midazolam
rosuvastatin Triazolam
Protease inhibitors Immunosuppressants Azole antifungals (except fluconazole and 
topical antifungals) ritonavir Cyclosporine
indinavir TacrolimusDrug Design, Development and Therapy 2009:3 259
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organic solutes. Activation of cation channels leads to 
rapid movement of electrolytes whereas organic solute 
loss occurs later because it requires the synthesis of new 
transporters.52–54 How ODS develops is not completely 
understood, however, the mechanism appears to be that 
osmolytes cannot be quickly replaced as the brain volume 
shrinks in response to an elevation in the plasma [Na+] 
concentration.55 As a result, it is currently recommended that 
the plasma [Na+] concentration in hyponatremic patients be 
elevated at a maximum rate of 10 to 12 mEq/L during the 
first day and 18 mEq/L over the first 2 days.41,42
Rapid serum [Na+] correction was defined in conivaptan 
clinical trials by the occurrence of any of the following 
1) An increase in serum [Na+]  12 mEq/L in 1 day; 2) a total 
increase in serum [Na+] of more than 24 mEq/L; 3) serum 
[Na+]  145 mEq/L; or 4) reduced or temporarily withheld 
treatment after an increase in serum [Na+] judged to be 
too rapid. The reported prevalence of rapid correction 
in conivaptan clinical trials is 9% with no occurrence of 
permanent neurologic sequela. However, this prevalence 
was based mainly on one criterion, an increase of serum 
[Na+]  12 mEq/L in 24 hours and the prevalence may be 
somewhat higher if all above mentioned definitions were 
used. To date there has been no report of ODS with the 
use of conivaptan or any other VRAs.
Conivaptan in the treatment 
of hyponatremia
Animal studies
Antagonism of the V2 receptor increases free water excretion 
causing hypo-osmolar urine, enhanced diuresis, and increased 
plasma [Na+] levels. Several animal studies have demon-
strated the aquaretic effect of conivaptan (Table 4). Yatsu 
et al56 showed in conscious dogs that the administration of 
both oral and iv conivaptan resulted in a dose-dependent 
aquaresis. Tomura et al57 showed that oral conivaptan 
increased the urine volume and reduced the urine osmolality 
in dehydrated conscious rats and compared to furosemide 
the amount in [Na+] excretion was much lower. In a study 
in normal conscious rats by Risvanis et al,44 oral conivaptan 
caused a dose dependent increase in urine volume and fluid 
intake and decreased urine osmolality without natriuresis. 
Tahara et al45 showed that iv administration of conivaptan 
increased urine volume and reduced urine osmolality in a 
dose dependent manner in dehydrated rats and Wada et al58 
showed that iv conivaptan produced statistically significant 
Table 4 effect of conivaptan on urinary volume and [Na+] concentration in animals
References Species Condition  
of species
Intervention Results
risvanis et al44 rats  
 
(male Sprague-Dawley)
Normal  
 
Conscious
vehicle or 1 mg/kg iv or 3 mg/kg 
oral conivaptan
Dose-dependent increase in urine volume 
and decrease in urine osmolality without 
natriuresis
Tahara et al45 rats  
 
(male and female wistar)
Dehydrated   
 
Conscious
vehicle or 0.01 to 0.3 mg/kg iv 
conivaptan
increased urine volume and reduced urine 
osmolality in a dose-dependent manner
Yatsu et al56 Dogs  
 
 
(female Beagle)
Normal  
 
 
Conscious
Oral 0.03 to 0.3 mg/kg or 0.01 
to 0.1 mg/kg iv conivaptan or iv 
furosemide 0.3 mg/kg
Dose-dependent aquaresis
Tomura et al57 rats  
 
(male wistar)
Normal and 
dehydrated  
Conscious
1-dehydrated: 0.1, 0.3, 1,3 mg/kg oral 
conivaptan or furosemide 3, 10, 30, 
100 mg/kg  
 
2-hydrated: vehicle or 0.3, 1,3 mg/kg 
oral conivaptan or furosemide 
100 mg/kg
(1)   Dose-dependent increase in urine 
volume and reduction in urine osmolarity. 
increased urinary [Na+] excretion to a 
lower degree than furosemide
(2)   Dose-dependent increase in urine 
volume with longer duration of diuresis 
compared to furosemide
wada et al58 rats (n = 44) 
  
(male wistar)
SiADH  
 
Conscious
vehicle or 0.1, 1 mg/kg iv conivaptan   
vs 
 vehicle or furosemide 10 mg/kg
increased both blood [Na+] concentration 
and plasma osmolality vs no effect of 
furosemide on either  
iv furosemide did not increase either blood 
[Na+] concentration or plasma osmolality
Abbreviations: iv, intravenous; SiADH, syndrome of inappropriate secretion of antidiuretic hormone.Drug Design, Development and Therapy 2009:3 260
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increase in blood [Na+] concentration and plasma osmolality 
in rats with SIADH.
Human studies
The effects of conivaptan on serum [Na+] in patients with 
euvolemic and hypervolemic hyponatremia have been studied 
in 3 randomized, double-blinded, placebo-controlled clinical 
trials (two with oral and one with iv conivaptan) and in one 
open label iv study (Table 5).
In a study by Ghali et al,59 74 patients with euvolemic 
or hypervolemic hyponatremia as defined by serum 
[Na+] of 115 to 130 mEq/L were stratified by volume 
status and assigned randomly in 1:1:1 ratio to receive 
oral placebo, 40 mg/day or 80 mg/day conivaptan in 
2 divided doses. Euvolemic hyponatremia was present 
in 75% of patients. The primary efficacy end point was 
the change from baseline in serum [Na+] throughout the 
5 days of treatment, as measured by the serum [Na+] 
AUC. The conivaptan groups, 40 and 80 mg/day had 
least square (LS) mean change from baseline in serum 
[Na+] AUC during the 5-day treatment that was 2-fold 
(P = 0.03) and 2.5-fold (P  0.001) greater, respectively, 
than placebo. Also, the efficacy on secondary end points 
was consistent including shorter median time to achieve 
a confirmed increase in serum [Na+] of 4 mEq/L or 
more from baseline (P  0.044 for the 40 mg/day and 
P  0.002 for the 80 mg/day conivaptan), a longer mean 
total times during which patients had a serum [Na+] level 
of 4 mEq/L or more above baseline (P  0.001), a greater 
LS mean change in serum [Na+] from baseline to end 
of treatment (P  0.002) and a higher percentage of a 
confirmed normal serum [Na+]  135 mEq/L or increase 
of 6 mEq/L or more (P  0.014).
In the recently published multicenter European 
study by Annane et al60 83 patients with euvolemic 
or  hypervolemic  hyponatremia  with  serum  [Na+] 
 130 mEq/L, plasma osmolarity 290 mOsmol/kg H2O 
and no evidence of extracellular volume depletion 
were divided into three different groups and received 
conivaptan 20 mg twice daily (40 mg/day), conivaptan 
40 mg twice daily (80 mg/day), or placebo for 5 days 
as inpatients. All patients were prescribed fluid restric-
tion and diuretic doses were stabilized before screening 
and remained constant throughout the study. Euvolemic 
hyponatremia was present in 63% at baseline, and the 
most common single causes of hyponatremia were heart 
failure (33%) and cancer (17%). The primary efficacy 
end point was the change from baseline in serum [Na+] 
throughout the 5 days of treatment, as measured by the 
serum [Na+] AUC. Conivaptan produced a dose-dependent 
and significantly greater increase in serum [Na+] AUC 
than placebo (P  0.0001). The difference in serum [Na+] 
AUC between the 2 conivaptan doses was also statistically 
significant (P  0.028).
The efficacy on secondary endpoints was also 
consistent. Both doses of conivaptan achieved shorter 
median times from the first dose to a confirmed serum 
[Na+] increase of 4 mEq/L or greater from baseline 
(P  0.0004 for the 40 mg/day and P  0.0001 for the 
conivaptan 80 mg/day). Both groups were significantly 
different from the placebo group. The median time was not 
estimable in the placebo group (too few patients achieved 
an increase of 4 mEq/L or greater during the 5-day study). 
Moreover, the LS mean total time during which patients 
had an increase in serum [Na+] of 4 mEq/L or more from 
baseline was significantly greater among patients given 
conivaptan 40 mg/day and 80 mg/day compared to placebo 
(P  0.0001).
Both doses of conivaptan had greater LS mean ± SE 
change in serum [Na+] from baseline to the end of treat-
ment (P  0.0001). Similarly, both doses of conivaptan 
groups had a higher number of patients who demonstrated 
either a confirmed serum [Na+] of 6 mEq/L or more 
above baseline or normal serum [Na+] ( 135 mEq/L) 
(P  0.0008 for the 40 mg/day vs P  0.001 for the conivap-
tan 80 mg/day). Of note, 7 days after the study ended, both 
conivaptan groups had higher change in serum [Na+] than 
those in placebo group. Finally, conivaptan, in compari-
son with placebo, produced greater increases in free and 
effective water clearance, net fluid loss, plasma osmolal-
ity and greater reductions in urine osmolality and urine 
[Na+] levels.
Iv conivaptan has been shown to have similar effects 
on serum [Na+]. In a study by Zeltser et al,61 84 patients 
hospitalized with euvolemic and hypervolemic hyponatremia, 
with serum [Na+] of 115 mEq/L to 130 mEq/L were 
randomized to receive placebo or 20 mg of conivaptan as 
a bolus iv dose, followed by a continuous infusion of 40 or 
80 mg per day for 4 days. Both conivaptan doses increased 
[Na+] AUC during the 4-day treatment (P  0.0001 vs 
placebo) and the LS mean changes in serum [Na+] at 
day 4 for the 3 respective groups were significanly greater 
with conivaptan (P  0.001) and so was the percentage 
of patients achieving 6 mEq/L or more increase in serum 
[Na+] from baseline or normalization of [Na+] (defined 
as 135 mEq/L) (P  0.001). The median time from the Drug Design, Development and Therapy 2009:3 261
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first dose to 4 mEq/L increase in serum [Na+] was 23.7 hours 
and 23.4 hours for the conivaptan 40 mg/day and 80 mg/day 
groups, respectively (P  0.001).
In all of these randomized studies, the magnitude of 
changes in serum [Na+] was clinically significant. One might 
speculate that the design of these studies could have been 
benefited by separating the included patient population by 
the etiology of hyponatremia or by stratifying randomization 
by etiology (heart failure vs SIADH). In addition, detailed 
information on fluid input and output would have provided 
additional information. Finally, a serial measurement of 
serum [Na+] over extent period of time would have shed light 
on the duration of corrected hyponatremia and the frequency 
with which it persists.
Verbalis et al conducted an open-label trial62 investigating 
4 days treatment with iv conivaptan The magnitude of changes 
in serum [Na+] sodium is clinically significant: 20 mg/day 
(n = 37) or 40 mg/day (n = 214) in patients with euvolemic 
or hypervolemic hyponatremia. Patients received a loading 
dose of iv conivaptan 20 mg as a 30-minute infusion 
followed by a continuous iv infusion of conivaptan 20 or 
40 mg/day for 4 days. The primary efficacy point was base-
line adjusted serum [Na+] area under the curve over the 
duration of treatment, which was 753.8 mEq ⋅ h/L +429.9 
in the 20 mg/day group and 689.2 mEq ⋅ h/L + 417.3 in the 
40 mg/day group.
Only iv conivaptan has been approved for use in 
hospitalized patients with euvolemic and hypervolemic 
hyponatremia. The development of the oral formulation was 
stopped because of multiple drug–drug interactions due to 
inhibition of CYP3A4 in intestine and liver that is involved 
in the metabolism of many drugs especially cardiovascular 
medications.
Use of conivaptan in heart failure
Heart failure is characterized by neurohormonal activation 
that plays a central role in [Na+] and water retention. Several 
mechanisms mediate volume overload and hyponatremia in 
heart failure, and both hyponatremia and congestion share 
many common pathophysiological pathways including 
activation of the SNS, the RAAS and AVP.24 Antagonism 
of the multiple actions mediated by AVP and the potential 
beneficial effect of conivaptan in heart failure has been 
investigated in several studies.
Animal studies
AVP has been shown, through the activation of V1A receptor, 
to increase the rate of protein synthesis in the myocardium 
leading to myocyte hypertrophy in rats63–66 (Table 6). In a 
study by Tahara et al,65 conivaptan was demonstrated to 
have dose-dependent inhibition of the AVP-induced protein 
synthesis in neonatal rat cardiomyoctes. Similar effects of 
conivaptan were demonstrated in another study by Tahara 
et al65 in rat vascular smooth muscles.66
The effects of conivaptan on the hemodynamics in heart 
failure have also been studied in multiple animal models 
(Table 6).
Conivaptan reversed the decrease in cardiac output and 
the increase in total peripheral resistance induced by AVP 
in dogs without heart failure.67 In a dog model with pacing 
induced heart failure, iv conivaptan increased cardiac output 
and stroke volume, reduced preload and afterload, increased 
urine flow and decreased urine osmolarity.68
In rats with myocardial infarction induced heart failure, 
both oral and iv conivaptan increased myocardial contractility 
and reduced right atrial and both right and left ventricular end 
diastolic pressures compared to control.69 It also increased 
urine volume and reduced urine osmolarity in rats with and 
without coronary heart failure.70
Human studies (Table 7)
Several studies have been performed to assess the effects of 
conivaptan in heart failure (Table 7). A hemodynamic double-
blinded, randomized, placebo-controlled study of 142 patients 
with heart failure (NYHA class III and IV) receiving a single 
dose of iv conivaptan demonstrated a significant reduction 
in pulmonary capillary wedge pressures (P  0.05) and 
right atrial pressure (P  0.05) compared to placebo. The 
hemodynamic improvements were accompanied by increased 
urine output (P  0.001) without affecting renal function. 
There were no significant changes in cardiac index, systemic 
and pulmonary vascular resistance, blood pressure and heart 
rate compared to placebo.71
The effects of conivaptan on heart failure symptoms and 
functional capacity were evaluated in a 12-week oral adminis-
tration study, A Dose Evaluation of a Vasopressin Antagonist 
in CHF Patients undergoing Exercise (ADVANCE).72 Among 
345 patients with class II–IV heart failure, randomized to oral 
conivaptan 10, 20, 40 mg twice daily or placebo, there was no 
significant difference in exercise tolerance, as measured by 
the time to reach 70% of peak oxygen consumption, between 
conivaptan and placebo.
In recent double blinded, multicenter study,48 the use 
of conivaptan was evaluated in 170 patients admitted with 
acute decompensated heart failure with worsening dyspnea 
and pulmonary vascular congestion. The mean age was Drug Design, Development and Therapy 2009:3 262
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Table 5 Conivaptan studies in patients with hyponatremia
Baseline Na+ Ghali et al59 Annane et al60 Zeltser et al61 Verbalis et al62 Ghali et al73
Total number  
of patients
74 83 84 251 HF 98 No HF 237
_ Placebo 20 mg 40 mg 80 mg Placebo 20 mg 40 mg 80 mg 
(whites)
Ethnicity 89%   whites 100%   whites 85.7%   whites 78 90 83 63 95 85 92 78
Females 51.4% 33.7% 51.2% _ 44 60 54 38 50 67 70 50
Age  65 68% 47% 71.4% _ 89 80 79 63 90 89 74 78
Age _ _ _ _ 75.7 69 73.1 70.8 75.7 75.1 71.7 73.7
Euvolemic % 75% 62.7% 66.7% _
Design Double-blinded,  
placebo-controlled
Double-blinded,  
placebo-controlled
Double-blinded,  
placebo-controlled
Open label Double-blind placebo-controlled (n = 184) open label (n = 251)
iv or oral conivaptan Oral Oral iv iv iv
Dose of conivaptan Placebo or conivaptan  
40 or 80 mg/d in 2 divided doses
Placebo or conivaptan  
40 or 80 mg/d in 2 divided doses
Placebo or 20 mg of conivaptan as a 
bolus iv dose, followed by a continuous 
infusion of 40 or 80 mg/d
Loading dose of iv conivaptan 20 mg followed by  
a continuous iv infusion of conivaptan  
20 or 40 mg/d
Loading dose of 20 mg followed by continous infusion 40 or 80 mg/d
Duration of treatment 5 days 5 days 4 days 4 days 4 days 4 days
Primary endpoint Placebo 40 mg/d  
(P)
80 mg/d  
(P)
Placebo 40 mg/d  
(P)
80 mg/d  
(P)
Placebo 40 mg/d  
(P)
80 mg/d  
(P)
20 mg/d 80 mg/d Placebo 20 mg/d 40 mg/d 80 mg/d Placebo 20 mg/d 40 mg/d 80 mg/d
LS mean change from 
baseline in serum [Na+]  
AUC during the 5-day  
treatment ± Se (meq h/L)
309.2 621.3  
(0.03)
836.2  
(0.001)
88 ± 81 634 ± 84  
(0.0001)
953 ± 86  
(0.0001)
12.9 490.9  
(0.001)
716.6  
(0.001)
753.8 689.2 93 459.0 579.0 576.0 47.0 867.0 703.0 700.0
Secondary endpoints Placebo 40 mg/d  
(P)
80 mg/d  
(P)
Placebo 40 mg/d  
(P)
80 mg/d  
(P)
Placebo 40 mg/d  
(P)
80 mg/d  
(P)
20 mg/d 80 mg/d Placebo 20 mg/d 40 mg/d 80 mg/d Placebo 20 mg/d 40 mg/d 80 mg/d
Time to a confirmed 
increase in serum [Na+]  
 4 meq/L from baseline  
(median h)
71.7 27.5  
(0.044)
12.1  
(0.002)
_ 23.5  
(0.0004)
8.7  
(0.0001)
_ 23.7  
(0.001)
23.4  
(0.001)
_ _ Ne 30.0 28.0 24.0 Ne 18.0 24.0 8.0
Total time serum  
[Na+]  4 meq/L above  
baseline [LS mean (Se)⋅h]
46.5 69.8  
(0.103)
88.8  
(0.001)
20.3 68.8  
(0.0001)
86.6  
(0.0001)
14.2 53.2  
(0.001)
72.7  
(0.001)
_ _
Change in serum [Na+] to 
end of treatment  
[LS mean (Se) meq/L]
3.4 6.4  
(0.081)
8.2  
(0.002)
1.6 7.2  
(0.0001)
9.1  
(0.0001)
0.8 6.3  
(0.001)
9.4  
(0.001)
_ _ 3.0 7.9 7.9 9.0 3.1 9.8 8.1 9.4
Patients with a confirmed  
normal serum [Na+]  
( 135 meq/L)  
or increase of 6 meq/L  
[no. (%)]
11 17  
(0.111)
22  
(0.014)
20 66.7  
(0.0008)
88.5  
(0.0001)
20.7 69  
(0.001)
23  
(0.001)
_ _ 11 50 63 88 25 78 75 89
Abbreviations: AUC, area under the curve; iv, intravenous; HF, heart failure; Ne, not estimable. 
63.5 years and 63% were males. The mean left ventricular 
ejection fraction was 29.5% and 91% had NYHA class III and 
IV heart failure. Patients were randomized to receive 20 mg 
conivaptan or placebo loading dose, followed by 40, 80, or 
120 mg/day conivaptan or placebo by continuous iv infusion 
for 2 days. Despite the increase in total urine output (P  0.02) 
and the trend for a decrease in body weight), patient-assessed 
severity of respiratory symptoms did not improve.
A pooled analysis of a randomized controlled trial61 
and an open-label trial62 evaluated the efficacy and safety 
of conivaptan in 335 patients with euvolemic or hyper-
volemic hyponatremia with or without underlying heart 
failure. Conivaptan (20 mg loading dose followed by 4-day 
continuous infusion of 40 or 80 mg/day in the randomized 
controlled trial and 20 or 40 mg/day in the open-label trial) 
produced prompt but controlled increases in serum [Na+] Drug Design, Development and Therapy 2009:3 263
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Table 5 Conivaptan studies in patients with hyponatremia
Baseline Na+ Ghali et al59 Annane et al60 Zeltser et al61 Verbalis et al62 Ghali et al73
Total number  
of patients
74 83 84 251 HF 98 No HF 237
_ Placebo 20 mg 40 mg 80 mg Placebo 20 mg 40 mg 80 mg 
(whites)
Ethnicity 89%   whites 100%   whites 85.7%   whites 78 90 83 63 95 85 92 78
Females 51.4% 33.7% 51.2% _ 44 60 54 38 50 67 70 50
Age  65 68% 47% 71.4% _ 89 80 79 63 90 89 74 78
Age _ _ _ _ 75.7 69 73.1 70.8 75.7 75.1 71.7 73.7
Euvolemic % 75% 62.7% 66.7% _
Design Double-blinded,  
placebo-controlled
Double-blinded,  
placebo-controlled
Double-blinded,  
placebo-controlled
Open label Double-blind placebo-controlled (n = 184) open label (n = 251)
iv or oral conivaptan Oral Oral iv iv iv
Dose of conivaptan Placebo or conivaptan  
40 or 80 mg/d in 2 divided doses
Placebo or conivaptan  
40 or 80 mg/d in 2 divided doses
Placebo or 20 mg of conivaptan as a 
bolus iv dose, followed by a continuous 
infusion of 40 or 80 mg/d
Loading dose of iv conivaptan 20 mg followed by  
a continuous iv infusion of conivaptan  
20 or 40 mg/d
Loading dose of 20 mg followed by continous infusion 40 or 80 mg/d
Duration of treatment 5 days 5 days 4 days 4 days 4 days 4 days
Primary endpoint Placebo 40 mg/d  
(P)
80 mg/d  
(P)
Placebo 40 mg/d  
(P)
80 mg/d  
(P)
Placebo 40 mg/d  
(P)
80 mg/d  
(P)
20 mg/d 80 mg/d Placebo 20 mg/d 40 mg/d 80 mg/d Placebo 20 mg/d 40 mg/d 80 mg/d
LS mean change from 
baseline in serum [Na+]  
AUC during the 5-day  
treatment ± Se (meq h/L)
309.2 621.3  
(0.03)
836.2  
(0.001)
88 ± 81 634 ± 84  
(0.0001)
953 ± 86  
(0.0001)
12.9 490.9  
(0.001)
716.6  
(0.001)
753.8 689.2 93 459.0 579.0 576.0 47.0 867.0 703.0 700.0
Secondary endpoints Placebo 40 mg/d  
(P)
80 mg/d  
(P)
Placebo 40 mg/d  
(P)
80 mg/d  
(P)
Placebo 40 mg/d  
(P)
80 mg/d  
(P)
20 mg/d 80 mg/d Placebo 20 mg/d 40 mg/d 80 mg/d Placebo 20 mg/d 40 mg/d 80 mg/d
Time to a confirmed 
increase in serum [Na+]  
 4 meq/L from baseline  
(median h)
71.7 27.5  
(0.044)
12.1  
(0.002)
_ 23.5  
(0.0004)
8.7  
(0.0001)
_ 23.7  
(0.001)
23.4  
(0.001)
_ _ Ne 30.0 28.0 24.0 Ne 18.0 24.0 8.0
Total time serum  
[Na+]  4 meq/L above  
baseline [LS mean (Se)⋅h]
46.5 69.8  
(0.103)
88.8  
(0.001)
20.3 68.8  
(0.0001)
86.6  
(0.0001)
14.2 53.2  
(0.001)
72.7  
(0.001)
_ _
Change in serum [Na+] to 
end of treatment  
[LS mean (Se) meq/L]
3.4 6.4  
(0.081)
8.2  
(0.002)
1.6 7.2  
(0.0001)
9.1  
(0.0001)
0.8 6.3  
(0.001)
9.4  
(0.001)
_ _ 3.0 7.9 7.9 9.0 3.1 9.8 8.1 9.4
Patients with a confirmed  
normal serum [Na+]  
( 135 meq/L)  
or increase of 6 meq/L  
[no. (%)]
11 17  
(0.111)
22  
(0.014)
20 66.7  
(0.0008)
88.5  
(0.0001)
20.7 69  
(0.001)
23  
(0.001)
_ _ 11 50 63 88 25 78 75 89
Abbreviations: AUC, area under the curve; iv, intravenous; HF, heart failure; Ne, not estimable. 
that were often evident by the end of day 1 of treatment. By 
the end of treatment most conivaptan-treated patients with or 
without heart failure achieved a  6 mEq/L increase in serum 
[Na+] above baseline or a normal serum [Na+] concentration 
(135 mEq/L).
Patients with heart failure demonstrated a lower 
increase in serum [Na+] AUC, a longer time to a con-
firmed 4 mEq/L increase in serum [Na+], and a lower 
likelihood of a 6 mEq/L increase in serum [Na+] or a normal 
serum [Na+] compared to those without heart failure.
Another issue that has not been adequately addressed 
is fluid restriction. On one hand, adherence to strict fluid 
restriction may result in hypernatremia but on the other, 
liberalization of fluid intake may limit the extent of fluid 
removal in patients with decompensated heart failure and 
fluid overload.Drug Design, Development and Therapy 2009:3 264
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Table 6 effect of conivaptan on myocardial cells hemodynamics in heart failure animals
References Species Condition of species Intervention Results
Tahara et al65 Neonatal rat 
cardiomyocytes  
(wistar rats)
Cultured cells YM087 (conivaptan) Dose dependent inhibition of AvP induced 
protein synthesis
Tahara et al66 rat vascular 
smooth muscle 
cells
Cultured cells YM087 (conivaptan) Prevented AvP-induced hyperplasia and 
hypertrophy of these cells in concentration 
dependent manner
Yatsu et al67 Dogs (n = 8)  
(male and female 
Beagle)
Pacing-induced HF  
Anesthetized
vehicle or 0.1 mg/kg iv conivaptan increased cardiac output and stroke 
volume, reduced LveDP and TPr, increased 
urine flow and decreased urine osmolarity
Yatsu et al68 Dogs (n = 11)  
(male and female 
mongrel dogs)
Normal  
Anesthetized
AvP infusion followed by iv bolus of 
0.9% saline followed by 0.1 mg/kg iv 
conivaptan
rapidly attenuated the AvP induced 
decrease in CO and reversed the AvP 
induced elevation in both LveDP and TPr
wada et al69 rats Mi-induced HF 
(n = 30) 
Conscious  
vs  
Sham operated control 
rats 
Conscious
Aquaretic effect: (n = 30) 
vehicle or 0.03, 0.1, 0.3 mg/kg iv conivaptan   
Or 0.3 mg/kg v2r antagonist Sr121463A  
 
Hemodynamic effect: (n = 39)  
vehicle or 0.1, 0.3 mg/kg iv conivaptan  
Or 0.3 mg/kg v2r antagonist Sr121463A
Dose dependent increase in urine volume 
and reduction of urine osmolality in both 
HF and sham-operated rats. Sr121463A 
had similar effects to conivaptan
reduction of rv systolic and rA pressures, 
LveDP, lung and body weight. increased 
dP/dtmax/LvP
Sr121463A caused similar effects except it 
did not improve dP/dtmax/LvP
wada et al70 rats (n = 19)  
(male wistar)
Mi-induced HF  
vs  
Sham operated control 
rats 
 
Conscious
Aquaretic effect:  
 
vehicle or 0.3 to 3 mg/kg oral conivaptan   
Hemodynamic effect:  
 
vehicle or 3 mg/kg oral conivaptan
Higher AvP level in HF compared to sham 
operated rats 
reduction of LveDP, lung and rv weights 
and reduced mean blood pressure. No 
effect on heart rate or Lv systolic pressure 
Conivaptan also increased urine volume 
and reduced urine osmolarity
Abbreviations:   AvP, arginine vasopressin peptide; CO, cardiac output; HF, heart failure; iv, intravenous; Lv, left ventricle; LvP, left ventricular pressure; LveDP, left ventricle end 
diastolic pressure; Mi, myocardial infarction; rA, right atrium; rv, right ventricle;   TPr, total peripheral resistance.
Use of conivaptan in cirrhosis
Cirrhosis, like heart failure, is characterized by dilutional 
hyponatremia, impaired water excretion and persistent inap-
propriate AVP elevation by non-osmotic mechanisms. There is 
limited information about the use of conivaptan in this setting. 
In one study in rats with cirrhosis, conivaptan has shown to 
increase urine volume and osmolarity without affecting arterial 
blood pressure and creatinine clearance.74 Theoretically, it may 
not be advisable to use conivaptan in patients with cirrhosis 
because of the possibility that V1A inhibition may result in 
splanchnic vasodilatation as well as interference with platelet 
aggregation, actions that may promote variceal bleeding.32
Other uses of AVP receptor blockers
Hyponatremia in the neurocritical 
care unit
The use of conivaptan in correcting hyponatremia in patients 
admitted to neurointensive care units was reported in two 
retrospective studies. The first study in 22 patients with 
hyponatremia (defined as [Na+]  136 mEq/L) showed a very 
favorable response to conivaptan given as a bolus followed 
by infusion. An increase of 6 mEq/L was noted in 86% of 
the patients with an average time of 13.1 hours and no patient 
experienced rapid over correction.75 In another study, 
correction of hyponatremia was evaluated in 19 patients 
admitted to a neurointensive care unit with the administra-
tion of conivaptan 20 or 40 mg bolus given over 30 minutes, 
and repeated bolus injections given 12 to 72 hours after the 
first with no subsequent infusion. Serum [Na+] increased by 
5.8 ± 3.2 mEq/L within 12 hours for an overall 71% response 
as defined by at least 4 mEq/L increase in serum [Na+] and 
52% manifesting a 6 mEq/L. An increase of 4 mEq/L was 
maintained for up to 72 hours in 69% of patients.76
Tumor lysis syndrome
Conivaptan was used to treat SIADH in a thirteen year-
old patient with large-cell lymphoma before and during Drug Design, Development and Therapy 2009:3 265
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chemotherapy administration. This allowed aggressive 
hydration to prevent tumor lysis syndrome while induc-
ing free-water excretion.77 Further studies are needed to 
assess the potential therapeutic use for conivaptan for this 
indication.
Future use of conivaptan
Conivaptan is distinguished from other VRAs by its 
antagonism of both V1A and V2 receptors; thus, in heart 
failure it offers a theoretical advantage by combining a 
potential of hemodynamic benefit and reverse remodeling in 
addition to diuresis. Experimentally, it has been demonstrated 
that combined antagonism of V1A and V2 receptors could 
induce more beneficial hemodynamic responses compared 
to antagonism of V1A receptors alone.78 Also, it is worth 
mentioning that in the single dose hemodynamic study, there 
was no correlation between urine output and the decrease 
in filling pressures suggesting the possibility of a salutary 
effect beyond diuresis. Furthermore, that study was carried 
on in stable patients with heart failure, therefore, the potential 
benefit of conivaptan in patients with acute decompensated 
heart failure, whether systolic or diastolic and particularly in 
those with hyponatremia has not been adequately explored 
and it should be further investigated.
The ability to administer conivaptan intravenously 
offers an opportunity to explore its usage in the treat-
ment of symptomatic hyponatremia in combination with 
hypertonic saline. Considering the ease of use of single 
or multiple injections rather than continuous infusion, the 
efficacy of this modality of administration should also be 
investigated.
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